Seven Fleet Capital Management LP Takes Position in Century Therapeutics, Inc. $IPSC

Seven Fleet Capital Management LP purchased a new stake in Century Therapeutics, Inc. (NASDAQ:IPSC) during the second quarter, according to its most recent disclosure with the SEC. The firm purchased 4,347,826 shares of the company’s stock, valued at approximately $10,652,174,000. Century Therapeutics makes up approximately 1.8% of Seven Fleet Capital Management LP’s holdings, making the stock its 11th biggest holding.

Other institutional investors also recently bought and sold shares of the company. Versant Venture Management LLC acquired a new position in shares of Century Therapeutics during the first quarter valued at approximately $27,495,000. Commodore Capital LP purchased a new stake in shares of Century Therapeutics during the first quarter worth approximately $19,652,000. BlackRock Inc. purchased a new stake in shares of Century Therapeutics during the second quarter worth approximately $19,825,000. Trails Edge Capital Partners LP acquired a new position in Century Therapeutics in the 2nd quarter valued at $10,130,674,000. Finally, Spruce Street Capital LP purchased a new position in Century Therapeutics in the 2nd quarter valued at $9,944,682,000. 50.20% of the stock is currently owned by institutional investors and hedge funds.

Century Therapeutics Price Performance

NASDAQ:IPSC opened at $2.14 on Thursday. The firm has a market capitalization of $387.49 million, a price-to-earnings ratio of -2.30 and a beta of 1.57. The company’s 50-day moving average is $2.17 and its two-hundred day moving average is $2.22. Century Therapeutics, Inc. has a 1-year low of $0.44 and a 1-year high of $3.04.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.06). As a group, equities analysts anticipate that Century Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Mizuho assumed coverage on shares of Century Therapeutics in a report on Wednesday, May 27th. They set an “outperform” rating and a $8.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Century Therapeutics in a research note on Thursday, July 2nd. Finally, Wall Street Zen downgraded shares of Century Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 27th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $4.75.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.